1WA
HQL

180 Wealth Advisors’s abrdn Life Sciences Investors HQL Stock Holding History

180 Wealth Advisors’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.06M Buy
152,829
+3,271
+2% +$57.8K 0.31% 84
2026
Q1 		$2.43M Sell
149,558
-4,767
-3% -$79.7K 0.28% 91
2025
Q4 		$2.59M Buy
154,325
+5,067
+3% +$85.1K 0.29% 81
2025
Q3 		$2.31M Buy
149,258
+6,160
+4% +$84.3K 0.28% 88
2025
Q2 		$1.83M Buy
143,098
+6,976
+5% +$86K 0.26% 102
2025
Q1 		$1.73M Buy
136,122
+1,247
+0.9% +$16.9K 0.28% 97
2024
Q4 		$1.77M Buy
134,875
+709
+0.5% +$10.2K 0.28% 89
2024
Q3 		$2.02M Sell
134,166
-2,065
-2% -$31.3K 0.32% 78
2024
Q2 		$2.01M Buy
136,231
+3,682
+3% +$49.8K 0.33% 76
2024
Q1 		$1.81M Buy
132,549
+9,554
+8% +$132K 0.32% 82
2023
Q4 		$1.69M Buy
122,995
+8,271
+7% +$102K 0.34% 82
2023
Q3 		$1.43M Buy
114,724
+5,725
+5% +$75.3K 0.32% 83
2023
Q2 		$1.46M Sell
108,999
-2,857
-3% -$39.4K 0.32% 83
2023
Q1 		$1.56M Buy
111,856
+2,398
+2% +$34.3K 0.36% 80
2022
Q4 		$1.62M Buy
109,458
+6,126
+6% +$88.8K 0.38% 79
2022
Q3 		$1.41M Buy
103,332
+8,341
+9% +$125K 0.39% 75
2022
Q2 		$1.38M Buy
94,991
+9,907
+12% +$150K 0.35% 79
2022
Q1 		$1.43M Buy
85,084
+16,554
+24% +$285K 0.31% 85
2021
Q4 		$1.19M Buy
68,530
+5,428
+9% +$109K 0.27% 97
2021
Q3 		$1.3M Sell
63,102
-470
-0.7% -$10.1K 0.29% 94
2021
Q2 		$1.38M Sell
63,572
-193
-0.3% -$3.9K 0.32% 91
2021
Q1 		$1.26M Buy
63,765
+6,359
+11% +$131K 0.31% 93
2020
Q4 		$1.19M Buy
57,406
+281
+0.5% +$5.19K 0.34% 83
2020
Q3 		$1.01M Sell
57,125
-943
-2% -$16.9K 0.38% 72
2020
Q2 		$1.1M Sell
58,068
-5,840
-9% -$100K 0.44% 58
2020
Q1 		$938K Buy
63,908
+4,890
+8% +$80.1K 0.49% 58
2019
Q4 		$1.05M Buy
59,018
+7,507
+15% +$123K 0.42% 70
2019
Q3 		$766K Buy
51,511
+10,921
+27% +$175K 0.34% 78
2019
Q2 		$664K Buy
40,590
+5,180
+15% +$85.3K 0.3% 96
2019
Q1 		$581K Buy
+35,410
New +$611K 0.26% 109

Other funds holding HQL

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

180 Wealth Advisors's HQL Position: Q2 2026 in Review

180 Wealth Advisors increased its abrdn Life Sciences Investors (HQL) stake by 2.2% in Q2 2026, buying an estimated $57.8K and bringing the position to 152,829 shares worth $3.06M. The position accounts for 0.31% of the portfolio, ranked #84.

180 Wealth Advisors first reported a position in HQL in Q1 2019 and has held it in 30 quarters since. 83 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

  • 180 Wealth Advisors held 152,829 shares of abrdn Life Sciences Investors worth $3.06M as of Q2 2026.
  • 180 Wealth Advisors bought 3,271 abrdn Life Sciences Investors shares in Q2 2026, an estimated $57.8K.
  • abrdn Life Sciences Investors made up 0.31% of 180 Wealth Advisors's portfolio in Q2 2026, its #84 holding.
  • 180 Wealth Advisors first reported a position in abrdn Life Sciences Investors in Q1 2019 and has held it in 30 quarters since.
  • 83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on 180 Wealth Advisors's 13F filing for Q2 2026, filed 7 Jul 2026.